Pacific Biosciences Of California Inc Quick Ratio (PACB) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Pacific Biosciences Of California Inc   (NASDAQ: PACB)

Pacific Biosciences Of California Inc 's Quick Ratio

PACB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.01 below Pacific Biosciences Of California Inc average.

Within Laboratory Analytical Instruments industry 6 other companies have achieved higher Quick Ratio than Pacific Biosciences Of California Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 660 to 901.

Explain Quick Ratio?
How much Cash & cash equivalents PACB´s has?
What are PACB´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PACB/financial-strength
https://api.csimarket.com/api/v1/companies/PACB/fundamentals
https://api.csimarket.com/api/v1/companies/PACB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PACB Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 81.98 %
Y / Y Cash & cash equivalent Change -32.96 %
Quick Ratio MRQ 3.01
PACB's Total Ranking # 901
Seq. Current Liabilities Change 61.27 %
Seq. Cash & cash equivalent Change -15.47 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 7
Healthcare Sector # 376
Overall Market # 901


Quick Ratio Statistics
High Average Low
34.39 6.45 0.92
(Mar 31 2021)   (Jun 30 2020)




Financial Statements
Pacific Biosciences Of California Inc 's Current Liabilities $ 67 Millions Visit PACB's Balance sheet
Pacific Biosciences Of California Inc 's Cash & cash equivalent $ 200 Millions Visit PACB's Balance sheet
Source of PACB's Sales Visit PACB's Sales by Geography


Cumulative Pacific Biosciences Of California Inc 's Quick Ratio

PACB's Quick Ratio for the trailling 12 Months

PACB Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 34.86 %
Y / Y Cash & cash equivalent TTM Growth -26.28 %
Quick Ratio TTM 4.62
Total Ranking TTM # 3748
Seq. Current Liabilities TTM Growth 16.22 %
Seq. Cash & cash equivalent TTM Growth -9.02 %


On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $66.59 millions, cumulative Quick Ratio decreased to 4.62 below the Pacific Biosciences Of California Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Laboratory Analytical Instruments industry 21 other companies have achieved higher Quick Ratio than Pacific Biosciences Of California Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2797 to 3748.

Explain Quick Ratio?
How much Cash & cash equivalents PACB´s has?
What are PACB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Laboratory Analytical Instruments Industry # 22
Healthcare Sector # 872
Within the Market # 3748


trailing twelve months Quick Ratio Statistics
High Average Low
21.45 5.47 0.99
(Dec 31 2021)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Laboratory Analytical Instruments Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Alamar Biosciences Inc   6.77 $ 226.585  Millions$ 33.482  Millions
Standard Biotools Inc   5.24 $ 267.487  Millions$ 51.021  Millions
Eyepoint Inc   4.91 $ 189.113  Millions$ 38.507  Millions
10x Genomics Inc   4.10 $ 575.725  Millions$ 140.370  Millions
Pacific Biosciences Of California Inc   3.01 $ 200.217  Millions$ 66.593  Millions
Seer Inc   2.95 $ 29.316  Millions$ 9.942  Millions
Cytek Biosciences Inc   2.58 $ 255.899  Millions$ 99.179  Millions
Quanterix Corporation  1.51 $ 77.359  Millions$ 51.130  Millions
Nautilus Biotechnology Inc   1.07 $ 10.467  Millions$ 9.758  Millions
Precipio inc   0.90 $ 3.576  Millions$ 3.985  Millions
Bio rad Laboratories Inc   0.86 $ 837.100  Millions$ 969.100  Millions
Bionano Genomics Inc   0.66 $ 8.168  Millions$ 12.307  Millions
Revvity Inc  0.63 $ 592.799  Millions$ 936.977  Millions

Date modified: 2026-11-06T12:56:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.